These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 20977448)

  • 1. Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma.
    Klintman J; Astermark J; Berntorp E
    Br J Haematol; 2010 Nov; 151(4):381-6. PubMed ID: 20977448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.
    Livnat T; Martinowitz U; Azar-Avivi S; Zivelin A; Brutman-Barazani T; Lubetsky A; Kenet G
    Haemophilia; 2013 Sep; 19(5):782-9. PubMed ID: 23659442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma.
    Livnat T; Martinowitz U; Zivelin A; Seligsohn U
    Haemophilia; 2008 Jul; 14(4):782-6. PubMed ID: 18371162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay.
    Turecek PL; Váradi K; Keil B; Negrier C; Berntorp E; Astermark J; Bordet JC; Morfini M; Linari S; Schwarz HP
    Pathophysiol Haemost Thromb; 2003; 33(1):16-22. PubMed ID: 12853708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions.
    Aljamali MN; Kjalke M; Hedner U; Ezban M; Tranholm M
    Haemophilia; 2009 Nov; 15(6):1318-26. PubMed ID: 19659796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
    Luna-Záizar H; Beltrán-Miranda CP; Esparza-Flores MA; Soto-Padilla J; Bergés-García A; Rodríguez-Zepeda MD; Pompa-Garza MT; Jaloma-Cruz AR
    Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses.
    Kjalke M; Kjelgaard-Hansen M; Andersen S; Hilden I
    J Thromb Haemost; 2021 Jul; 19(7):1687-1696. PubMed ID: 33819375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
    Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
    Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. General haemostatic agents--fact or fiction?
    Hedner U
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor (F)VIII/VIIa enhances global haemostatic function in the co-presence of bypassing agents and FVIII among patients with haemophilia A with inhibitor.
    Nogami K; Matsumoto T; Yada K; Ogiwara K; Furukawa S; Shida Y; Takeyama M; Shima M
    Br J Haematol; 2018 May; 181(4):528-536. PubMed ID: 29611182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition.
    Doshi BS; Gangadharan B; Doering CB; Meeks SL
    PLoS One; 2012; 7(10):e48172. PubMed ID: 23144741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    Perzborn E; Heitmeier S; Laux V; Buchmüller A
    Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.
    Martinowitz U; Livnat T; Zivelin A; Kenet G
    Haemophilia; 2009 Jul; 15(4):904-10. PubMed ID: 19473416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated factor VIII enhances thrombin generation in the presence of factor VIII-deficiency, factor XI-deficiency or fondaparinux.
    Szlam F; Sreeram G; Solomon C; Levy JH; Molinaro RJ; Tanaka KA
    Thromb Res; 2011 Feb; 127(2):135-40. PubMed ID: 21144556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A.
    Klintman J; Berntorp E; Astermark J;
    Haemophilia; 2010 Jan; 16(1):e210-5. PubMed ID: 19878339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor.
    Livnat T; Martinowitz U; Zivelin A; Rima D; Kenet G
    Thromb Haemost; 2011 Apr; 105(4):688-95. PubMed ID: 21225093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
    Szlam F; Taketomi T; Sheppard CA; Kempton CL; Levy JH; Tanaka KA
    Anesth Analg; 2008 Mar; 106(3):719-24, table of contents. PubMed ID: 18292408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.
    Bhat V; von Drygalski A; Gale AJ; Griffin JH; Mosnier LO
    Thromb Haemost; 2016 Mar; 115(3):551-61. PubMed ID: 26466980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion.
    Carr ME; Martin EJ; Kuhn JG; Seremetis SV
    Thromb Haemost; 2003 May; 89(5):803-11. PubMed ID: 12719776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.